objective To analyse the outcomes of antiretroviral therapy (ART) in routine conditions in a rural hospital in the Far-North province of Cameroon. . At the end of the study period, 338 ⁄ 1187 had died and 59 ⁄ 1187 were lost to follow-up. The survival probability was 77% at 1 year [95% CI: 75-80] and 47% at 5 years [95% CI: 40-55]. The median survival time was 58 months. CD4 count, haemoglobin, BMI, sex and clinical stage at enrolment were independent predictors of mortality.
Introduction
Roughly 75% of AIDS patients in need of antiretroviral therapy (ART) in the world still have no access, and most of them live in Africa (World Health Organization 2006) . This, despite the fact that the three by five initiative of the World Health Organization (WHO), as well as the resources provided by the Global Fund, greatly facilitated access to ART in all regions of the world and boosted ART programs in most of sub-Saharan Africa, where the number of persons treated was multiplied by more than eight in just 2 years [World Health Organization (WHO) 2006] .
The clinical benefit of ART for AIDS patients, in terms of mortality reduction and improved quality of life, is well established but shows regional variations, with higher case fatality rates in poor countries (Braitstein et al. 2006; Egger 2007 ). There are several predictors of mortality for patients on ART: viral load, CD4 count, total lymphocytes, body mass index (BMI), and adherence. Although these determinants tend to be similar across the world, there are some striking differences in their relative frequency, e.g. the much lower baseline CD4 counts of patients starting ART in poor countries (Egger 2007 ).
The evidence on ART outcomes in sub-Saharan Africa mostly stems from research or pilot projects supported by international agencies (Laurent et al. 2005b ) depicting efficacy rather than effectiveness. Data on effectiveness, i.e. when ART is delivered in the routine operating conditions of hospitals with limited resources, are rare and often restricted by a small number of patients and ⁄ or short follow-up periods (Coetzee et al. 2004a; Akileswaran et al. 2005; Laurent et al. 2005b) . The question of ART effectiveness in real-life conditions still needs attention. Several authors have evoked the constraints faced, such as weak health systems and poor accessibility to health services (Bekker et al. 2003; Kabugo et al. 2005; Stevens et al. 2005 ; Organisation Mondiale de la Santé & ONUSIDA 2006) .
In Cameroon, the fight against HIV ⁄ AIDS is a priority since the launch of an HIV prevention programme early 2000. The HIV ⁄ AIDS control strategy 2006-2010 has three major objectives: preventing new HIV-infections, promoting universal access to AIDS care and reducing the impact of HIV ⁄ AIDS on children. ART care is provided at all levels of the health system and is mainly financed by the government (40%) and through the Global Fund (more than 50% since 2005). So far, the only clinical studies to evaluate the efficacy of ART in Cameroon were conducted in Douala and Yaoundé, two major cities located in the wealthier part of the country (Laurent et al. 2004 (Laurent et al. , 2005b (Laurent et al. , 2006 (Laurent et al. , 2007 Bourgeois et al. 2005) . The objective of our work was to document the outcome of ART in terms of survival and its determinants when provided in the rural and resource-constrained context of the Far-North Province of Cameroon.
Methods

Context
The Far-North Province of Cameroon (la Province de l'Extrème-Nord) extends over 34 246 km 2 and has a population of 3 551 944 inhabitants belonging to more than 50 ethnic groups. In 2004, HIV prevalence in this province was estimated at 2% in the population aged 15-49 years (Mosoko & Affana 2005) .
AIDS care in Cameroon is regulated by the government: ART has to be provided in specialized centres with an official accreditation: AIDS care at Petté includes management of opportunistic infections as well as first-line drugs (initially at 15 000 CFA (22 € ⁄ month) but since 2005 reduced to 3000 CFA or 4.5 € per month). Second-line ART was provided at 7000 CFA or 11.5 € per month. Prices mentioned are the subsidized prices patients have to pay out-of-pocket, though there is a mechanism to waive the fee partially or totally for those who cannot afford to pay. The ART protocols are standardized and in accordance with the WHO recommendations (WHO 2003) . The first line is one of the four following combinations: AZT + 3TC + NVP (DuovirÒ + NévumuneÒ), AZT + 3TC + EFV (DuovirÒ + StocrinÒ), D4T + 3TC + NVP (TriomuneÒ), D4T + 3TC + EFV (Lamivir-SÒ + StocrinÒ), with an estimated 70% of regimens being the fixed-dose combination TriomuneÒ. The second line consists of 2 NRTI + IDV, with DDI (VidexÒ) as the most commonly used NRTI. All patients with CD4 <350 cells ⁄ mm 3 receive cotrimoxazol prophylaxis.
At the start of ART, every patient benefits from adherence counselling. Every patient has to bring along a relative who is trained to support the patient in complying with treatment. Non-adherent patients are referred to special counselling sessions. Defaulters are actively traced by a messenger or by telephone.
The first follow-up visit is scheduled after 15 days, and on a monthly basis thereafter. CD4 monitoring is done on day 15, day 45, month 6 and every 6 months thereafter. 
Patients
All patients older than 15 years who were naïve to any antiretroviral therapy, and started ART between 1 July 2001 and 31 December 2006 at the ATC of Petté were eligible for this retrospective study. Patients who did not return for follow-up visits for more than 3 months were considered lost to follow-up. An intensive tracing effort by the ART centre in 2006 allowed updating the information on survival time and outcomes in many of those lost to follow-up. If they had died at home, they were categorized in the data analysis as having died immediately after the last registered follow-up visit, as for most of them the exact time of death was impossible to determine. A follow-up visit was considered 'on time' if it was not more than 3 days later than the date of appointment. If later, it was considered 'late' and if patient attended earlier than the appointment date, it was considered 'not scheduled'.
Data analysis
Since the start of the ART program in Petté, all patient data have been entered on a daily basis in an ACCESS database As the group 'lost-to-follow-up' may be more at risk of death than the others, a sensitivity analysis called 'the worst-case scenario' was carried out, in which all dropouts were classified as 'deceased' immediately after their last contact with the centre. Survival time was estimated by Kaplan-Meier curves. Survival curves for subgroups were compared by the logrank test. Cox proportional hazards models were fitted to identify independent determinants of survival. A number of possible predictors of mortality were unavailable for a significant proportion of patients. We explored the influence of these missing data using two approaches: (i) including 'Unknown' as a separate category in the model (Table 3 ) and (ii) adding those with unknown predictor to the reference category (data not shown).
Results were similar for both approaches. Changes in CD4 count and weight were summarized using mean and median changes from baseline and 95% confidence intervals (CIs) and tested using the Wilcoxon signed rank test. The CIs were calculated using the normal approximation with 1.58*interquartile (IQR) range as standard deviation of the median. The analysis was carried out with the software stata (version 9.0; StataCorp., 4905 Lakeway Drives, College Station, TX 77845, USA). Ethical clearance for the study was obtained from the National Ethical Committee of Cameroon.
Results
During the study period, 2161 HIV-positive persons were followed at the ATC in Petté. Between July 2001 and December 2006, 1279 patients were started on ART. We included 1187 treatment naïve patients over 15 years old in the analysis, who had at least one follow-up visit after the start of ART. Median age was 35 years (IQR 29-41) and 55.6% of patients were male. Out of 1187 patients, 1073 (90.4%) were started on ART at an advanced stage of the disease (WHO stage III or IV) ( Table 1 ). The main opportunistic infections observed during the initial visit (i.e. first contact with centre) were tuberculosis, pneumonia and skin infections. This spectrum remained stable over time (data not shown). Median CD4 count at ART initiation was 105 cells ⁄ mm 3 (IQR 40-173) and 306 (25.8%) patients had a CD4 count £50 cells ⁄ mm 3 . Fiftysix per cent of patients had a BMI £18.5 kg ⁄ m 2 . Table 2 shows how median CD4 count at initiation evolved by year of enrolment: no substantial increase over time was observed.
Of the 1187 patients followed, 570 (48.0%) were still under follow-up on 30 June 2007, 59 (5.0%) were lost to follow-up, 338 (28.5%) had died and 220 (18.5%) were transferred out. Total mortality rate over the study period was 20.2 per 100 person-years at risk (338 ⁄ 1677 personyears). In the worst-case scenario, considering all those lost to follow-up as deceased immediately after the last date of contact, mortality rate was estimated at 23.1 per 100 person-years at risk. The median survival time was 58 months (49 months in the worst-case scenario). The (Figure 2 ). At all timepoints there was a significant increase in weight compared to baseline (P £ 0.010), with an average weight gain at month 12 of 6.3 kg. In univariate analysis (not shown), patient survival under ART was significantly associated with clinical AIDS stage at start, baseline CD4 count, haemoglobin and lymphocyte count, with baseline BMI, sex, and % of visits on time while TB at initiation was not. In multivariate analysis, only baseline CD4, sex, BMI, baseline haemoglobin and WHO clinical stage remained significantly associated with survival (Table 3) . Percentage of visits on time was eliminated from the model because data were missing for more than 20% of patients. Patients with a baseline CD4 A BMI between 15 and 18.5 kg ⁄ m 2 was related to a 1.5 times higher risk of death than a BMI >18.5 kg ⁄ m 2 (HR = 1.57). This risk rose to three times more for those with a BMI £15 kg ⁄ m 2 . Patients in stage III and IV were two to four times more likely to die than patients in stage I and II. Men were at nearly twice the risk of death as women (HR = 1.7). Patients with haemoglobin £8.5 g ⁄ dl had two times more risk of death than those with a haemoglobin rate >8.5 g ⁄ dl (Table 3) .
The drug regimen was changed for 40 patients because of severe side effects (29) or because of therapeutic failure (11). All failures were followed up after month 12 of treatment. Close to 45% (13 ⁄ 29) of side effects arose after the 12th month, these were mainly peripheral neuropathy and lipodystrophy, attributable to D4T.
Discussion
This 5-year retrospective cohort study of AIDS patients on ART gives an insight in survival and its determinants in a rural hospital setting in Cameroon. The spectrum of patients enrolled in this centre was similar for many other start-up ART programs in resource poor settings. More than half of the patients were severely malnourished at baseline, and a very high proportion (26%) of them were in severe immune depression (CD4 count £50 cells ⁄ mm 3 ). Strikingly, the latter proportion stayed high, and above 18%, for each single year of the study period, implying that over time, patients did not get earlier access to ART. In our rural context, late uptake of Voluntary Counselling and Testing (VCT) services as well as the stigmatization and denial surrounding HIV ⁄ AIDS continues to lead to very late initiation of ART. It remains a challenge for integrated health services such as those provided at Petté, to stimulate earlier VCT uptake through the various entry points in the health system. Table 4 shows how results in Petté were somewhat inferior to those obtained in other resource-constrained settings (Laurent et al. 2002; Tassie et al. 2003; Coetzee et al. 2004a Laurent et al. 2004 Severe et al. 2005; Djomand et al. 2003) . In Petté, we observed a very important early mortality. Between 1 and 4 years on ART, the mortality risk was less pronounced, but appeared to increase again after 4 years, though the confidence interval around the survival probability at 5 years is very wide. A lot of factors could have contributed to the early mortality in our cohort, most importantly the fact that the majority of patients started ART in an advanced stage of the disease, and that this proportion apparently did not diminish over time. Table 4 Comparison of survival probability on ART in several studies
Ref.
Country n Persons at risk (n) and probability of survival (%) at several time-points The high mortality after 4 years on therapy is a finding that remains to be confirmed on a larger number of patients, and could be possibly related to undiagnosed treatment failure. In Cameroon, genotypic resistance to first line ART occurred at a rate of 3.2 to 7.1 per 100 person-years (95% CI 1.8-28.4) in Douala (Bourgeois et al. 2005; Laurent et al. 2006 ) and 16.4% in Yaounde (Laurent et al. 2006) . In Senegal, this resistance was observed in 12.5% of patients (Laurent et al. 2005a) while in Germany and Luxemburg, Van Vaerenbergh et al. (2002) observed 28% of resistance. In our setting, resistance was suspected in every patient presenting treatment failure (as defined by the WHO 2003 clinical and immunological criteria) for whom an adherence problem could be ruled out. A regimen switch to second line because of suspected resistance was reported in 11 patients (0.9%), or a rate of 0.6 for 100 person-years, a rate well inferior to other reports and most likely therapeutic failures were under-diagnosed in the cohort at Petté.
Risk of death was two to four times higher for patients with clinical AIDS at the start of ART. Mortality was roughly two times higher for patients who began ART with a severe immune-depression (CD4 <50 cell ⁄ ml). These results are similar to those described elsewhere (Hogg et al. 1999; Grabar et al. 2000; Weidle et al. 2002; Bekker et al. 2003; Coetzee et al. 2004a; Dabis et al. 2005; Ivers et al. 2005; Kabugo et al. 2005; Laurent et al. 2005b; Sterne et al. 2005; Crum et al. 2006; Etard et al. 2006; Kheang 2006; Egger 2007) . Despite the fact that more than 90% of the patients started ART in an advanced clinical stage, the gains in CD4 count and weight were impressive. These results are comparable to other reports from Cameroon (Laurent et al. 2004 (Laurent et al. , 2005b (Laurent et al. , 2006 (Laurent et al. , 2007 Bourgeois et al. 2005) and elsewhere (Bekker et al. 2003; Coetzee et al. 2004a; Dabis et al. 2005; Ivers et al. 2005; Kheang 2006; Weidle et al. 2006) . Patients with a BMI <15 kg ⁄ m 2 were at higher risk of death, a result also reported from Senegal, Cambodia and Malawi (Etard et al. 2006; Kheang 2006; Zachariah et al. 2006) . In 2004, a clinical trial conducted by Fawzi et al. 2004 documented the harmful role malnutrition plays in the clinical progression of AIDS in resource-poor settings. Considering the fact that 56.1% of our patients were malnourished at enrolment, strategies for nutritional rehabilitation should be adopted in ART care.
Male sex was a predictor of mortality with a risk almost double that of female sex (HR 1.73; 1.37-2.19). Several authors described gender differences in ART outcomes (Sterling et al. 2001; Moore et al. 2002; Kremer & Sonnenberg-Schwan 2003; Perez-Hoyos et al. 2003) , while others found none (Egger et al. 2002; Bourgeois et al. 2005; Nicastri et al. 2005; Braitstein et al. 2006; Etard et al. 2006; Zachariah et al. 2006) . Potential confounders as gender differences in treatment adherence, risk behaviour and financial accessibility could offer alternative explanations for such an association.
The proportion of loss to follow-up in this cohort was small (thanks to a tracing effort in 2006) and comparable to other data from the African region (Grabar et al. 2000; Bekker et al. 2003; Coetzee et al. 2004a; Bourgeois et al. 2005; Lawn et al. 2005; Etard et al. 2006; Zachariah et al. 2006) . Very recently, a systematic review by Rosen et al. (2007) of clinical outcomes in 33 ART cohorts in 13 African countries showed that reported mortality rates were inversely correlated to the proportion of loss to follow-up. This is corroborated in our cohort, as 5% of loss to follow but 20% overall mortality was found. The opening of six treatment units in the province end of 2005 and subsequent referral to a centre closer to home led to loss of information about a substantial number of patients in the last year of the cohort. If we assume that those remained alive and on therapy, the overall proportion of patient retention in the ART cohort was 66.55% and this compares favourably to the average of 60% observed during a 24 months follow-up in the programs mentioned above (Rosen et al. 2007) .
Our study cohort has a rather long observation period (>5 years) and reflects the operational realities of a busy district hospital where ART care is fully integrated with other clinical activities. These features contain at the same time the strengths and the weaknesses of this study. We were not able to determine the exact cause of the deaths, and to attribute them all to HIV overestimates the AIDS-related mortality rate. The data were collected retrospectively from patient files in a context of routine care and hence there might be a certain degree of underreporting of events. After the intensive tracing and home visiting of defaulters was conducted in 2006, the remaining number of 'loss to follow-up' in the database was low, but they were less likely to survive than the others as judged from their prognostic markers at baseline. Therefore, we evoked an extreme scenario in the data analysis considering that all defaulters had died immediately after their last visit to the centre. This worst-case scenario is probably over-estimating the true mortality risk, as in AIDS patients not on ART only 25-50% will have died after 1 year (Schneider et al. 2004) . Lastly, our estimation of survival time at 5 years was not very precise, and missing data prevented us from analysing the role of adherence on survival time, though several studies report this as an important determinant (Laniece et al. 2003; Coetzee et al. 2004b; Mannheimer et al. 2006; Robbins et al. 2007) , especially when ART is not provided for free (Crane et al. 2006; Oyugi et al. 2007) . The clinical outcomes of AIDS patients on ART in routine hospital practice in the Far-North Province of Cameroon are slightly inferior to those observed in research projects in other regions of sub-Saharan Africa. We noted an important early mortality as well as a trend to rising mortality after 4 years. The factors associated with survival were: baseline CD4 count, basic haemoglobin, BMI, clinical stage and sex. Our study, while confirming the clinical benefit of ART in rural areas of Africa, raises the challenge of earlier and timelier access to ART and that of maintaining this clinical benefit over time.
